CONNECT



## INHERITED EYE DISORDERS TESTING REQUISITION

|   |   |  |                             | //                          |
|---|---|--|-----------------------------|-----------------------------|
| Patient Last Name                       | Patient First Name                                |  | MI                          | Date of Birth (MM / DD / YY |
| Address                                 | City  | State<br>Patient discharged from<br>the hospital/facility: | Zip<br>Biological Sex:      | Phone                       |
| Accession #                             | Hospital / Medical Record #                       | Yes No   | Gender identity (if differe | nt from above):             |
| REPORTING RECIPIENTS                    |   |  |                             |                             |
| Ordering Physician                      |   | nstitution Name  |                             |                             |
| Email (Required for International Clien | ts)   | Phone  | Fax                         |                             |
| ADDITIONAL RECIPIENTS                   |   |  |                             |                             |
| Name                                    |   | Email  | Fax                         |                             |
| Name                                    |   | Email  | Fax                         |                             |
| PAYMENT (FILL OUT ONE OF THE O          |   |  |                             |                             |
| Institution Name                        | Institution Code Institu                          | tion Contact Name Ir                                       | stitution Phone             | Institution Contact Email   |
| O INSURANCE                             |   |  |                             |                             |
| Do Not Perform Test Until Pa            | atient is Aware of Out-Of-Pocket Costs (excludes  | prenatal testing)  |                             |                             |
| REQUIRED ITEMS 1. Copy of               | the Front/Back of Insurance Card(s) 2. ICD10 Diag | gnosis Code(s) 3. Name of Orderin                          | g Physician 4. Insured 9    | Signature of Authorization  |
| Name of Insured                         | ///////   | Name of Insured  |                             | / / / /                     |
|   |   |  |                             |                             |
| Patient's Relationship to Insured       | Phone of Insured                                  | Patient's Relationship to                                  | Insured Ph                  | one of Insured              |
| Address of Insured                      |   | Address of Insured   |                             |                             |
| City                                    | State Zip   | City   | Sta                         | ite Zip                     |
| Primary Insurance Co. Name              | Primary Insurance Co. Phone                       | Secondary Insurance Co.                                    | Name Se                     | condary Insurance Co. Phone |
| Primary Member Policy #                 | Primary Member Group #                            | Secondary Member Polic                                     | cy # Se                     | condary Member Group #      |
|   |   |  |                             |                             |

| Patient's Printed Name  | Patient's Signature  | / /<br>Date (MM / DD / YYYY)   |
|---|--|--|
| STATEMENT OF MEDICAL NECESSITY (REQUIRED)   |  |  |
| This test is medically necessary for the risk assessment, diagnosis, or<br>patient's medical management and treatment decisions. The person lis<br>provided genetic testing information to the patient and they have cons | detection of a disease, illness, impairment, symptom, syndrome, or disou<br>ted as the Ordering Physician is authorized by law to order the test(s) req<br>ented to genetic testing. | rder. The results will determine my<br>juested herein. I confirm that I have |

BAYLORGENETICS.COM

\_\_\_/ \_\_\_ / \_\_\_\_ Date (MM / DD / YYYY)

Physician's Signature

Physician's Printed Name



CONNECT

# INHERITED EYE DISORDERS TESTING REQUISITION

|  |   |                                    | / /   |  |                       |
|--|---|------------------------------------|---|--|-----------------------|
| Patient Last Name  | Patient First Name  | MI                                 | Date of Birth (MM / DD /  | YYYY) Biological Sex   |                       |
| ETHNICITY  |   |                                    |   |  |                       |
|  |   |                                    |   | Philippings Microposia Malaysia Ind  | onocia)               |
|  |   |                                    |   | Philippines, Micronesia, Malaysia, Indi  | onesia)               |
|  |   |                                    |   |  |                       |
|  |   | q, Turkey)                         |   | (Vietnam, Cambodia, Thailand)  |                       |
| Finnish  | Native American   |                                    | Southern Europe   | ean Caucasian (Spain, Italy, Greece)   |                       |
| French Canadian  | Northern European Caucasian (Scandin                                | avian, UK, Germany)                | Other (Specify):  |  |                       |
| INDICATION FOR TESTING (REQUIRE  | D)  | SAMPLE                             |   |  |                       |
| Symptomatic (Summarize below)  | Symptomatic with Family History                                     | SAMPLE TYP                         | 'E  |  |                       |
|  |   | O Blood in E                       | DTA-tube (purple-top)   | 🔘 DNA  |                       |
|  |   | O Blood in H                       | leparin-tube (green-top)  | 🔘 Saliva   |                       |
| Asymptomatic   |   | Cultured                           | Skin Fibroblast   | Skin Biopsy  |                       |
| O Population Screening   | O Positive Family History   | Other (Sp                          | ecify)  | ◯ Tissue   |                       |
|  |   | NOTE: Extra                        | cted DNA/RNA will only be acc                                   | epted if the isolation of nucleic acids fo   | or                    |
| Disease  | Gene Variant  | clinical testing<br>requirements a | occurs in a CLIA-certified lab<br>is determined by the CAP and/ | poratory or a laboratory meeting equivator the CMS.  | alent                 |
| ICD10 Diagnosis Code(s):   |   | Blood should                       | not be sent from patients                                       |  |                       |
|  |   | who have had<br>or recent blo      | a bone marrow transplant<br>od transfusion                      | t / /  |                       |
|  |   |                                    |   | Date of Collection (MM/DD/   | /YY)                  |
| TESTING OPTIONS  |   |                                    | ••••••  |  | • • • • • • • • • • • |
| Targeted Sequencing for Known Far<br>and gene below and complete section | nilial Mutation (If selected, specify test code<br>on to the right) | FOR TARGETE                        | D TESTING SELECTION ONL   | Y  |                       |
|  |   | Proband Last                       | Name  | Proband First Name   |                       |
|  |   | /                                  | /   |  |                       |
| Test Code  | Gene  | Date of Birth (                    | MM/DD/YY)   | Relationship of Proband to Patie   | nt                    |
| Full Gene Sequencing   |   | Proband testir                     | ng location (Select one)  |  |                       |
| Deletion/ Duplication Analysis   |   |                                    |   |  |                       |
|  |   | 🗌 Baylor Ger                       | etics Lab#  | Family#  |                       |
|  |   | Another la                         | 1. Attach a co<br>boratory 2. A positive c<br>Please prov       | py of the Proband test results<br>ontrol sample of the Proband is rec<br>vide, if available. | quested.              |

### INHERITED EYE DISORDERS TESTS

#### CYTOGENETIC TESTS ·····

| TEST | CODE | TEST NAME  | SAMPLE TYPE*            | SPECIFY GENE OF INTEREST | SPECIFY REGION OF INTEREST |
|------|------|--|-------------------------|--------------------------|----------------------------|
|      | 8665 | Chromosomal Microarray Analysis (CMA) - HR + SNP Screen<br>(Comprehensive) | BE, DNA, CF,<br>SB, BUC |                          |                            |
|      | 8655 | Chromosomal Microarray Analysis (CMA) - HR                                 | BE, DNA, CF,<br>SB, BUC |                          |                            |

#### MITOCHONDRIAL DNA (MTDNA) MUTATION SCREENS

| TEST CODE | TEST NAME   | SAMPLE TYPE*   |
|-----------|---|----------------|
| 2010      | Advanced mtDNA Point Mutations and Deletions by Massively Parallel Sequencing (BCM-MitomeNGSSM) | BE, DNA, CF, T |
| 2055      | Comprehensive mtDNA Analysis by Massively Parallel Sequencing (BCM-MitomeNGSSM)                 | BE, DNA, CF, T |

\* Refer to Sample Specifications Table (page 5)



# 

## INHERITED EYE DISORDERS TESTING REQUISITION

|                   |                    |    | _ / _ / / _                    |                |
|-------------------|--------------------|----|--------------------------------|----------------|
| Patient Last Name | Patient First Name | MI | Date of Birth (MM / DD / YYYY) | Biological Sex |
|                   |                    |    |                                |                |
| FISH STUDIES      |                    |    |                                |                |

#### MASSIVELY PARALLEL SEQUENCING (BCM-MITOMENGSSM) PANELS ·······

| TEST CODE | TEST NAME  | SAMPLE TYPE*            | TEST CODE | TEST NAME   | SAMPLE TYPE*            |
|-----------|--|-------------------------|-----------|---|-------------------------|
| 20100     | Albinism Panel (13 genes)  | BE, DNA, CF,<br>SA, BUC | 5255      | Primary Open Angle Glaucoma Panel (MYOC, OPTN)        | BE, DNA, CF,<br>SA, BUC |
| 5260      | Developmental Glaucoma Panel (8 genes)                                       | BE, DNA, CF,<br>SA, BUC | 2140      | Progressive External Ophthalmoplegia Panel (10 genes) | BE, DNA, CF,<br>SA, BUC |
| 5250      | Familial Exudative Vitreoretinopathy Panel<br>(FZD4, LRP5, NDP, and TSPAN12) | BE, DNA, CF,<br>SA, BUC | 2190      | Retinitis Pigmentosa + RPGR orf15 by NGS (66 genes)   | BE, DNA, CF,<br>SA, BUC |
| 5090      | Leber Congential Amaurosis Panel (19 genes)                                  | BE, DNA, CF,<br>SA. BUC | 2195      | Usher Syndrome Panel (9 genes)                        | BE, DNA, CF,<br>SA. BUC |

DNA COPY NUMBER ANALYSIS

| TES | T CODE | TEST NAME  | SAMPLE TYPE* | SPECIFY GENE OF INTEREST        |  |  |
|-----|--------|--|--------------|---------------------------------|--|--|
|     | 2000   | MitoMet®Plus aCGH Analysis                                     | BE           | ////X///X///X///X////X////X//// |  |  |
|     | 2001   | Oligonucleotide Targeted Array Analysis (Single Target Gene)   | BE           |                                 |  |  |
|     | 2003   | Oligonucleotide Targeted Array Analysis (Up to 5 Target Genes) | BE           |                                 |  |  |

#### SINGLE GENE ANALYSIS ·····

If a test is not found on this form, please obtain the test code from our website (www.BMGL.com) and write in the below space(s).

| Test Code | Gene                             | Test Code              | Gene                  | Test Code       | Gene         |
|-----------|----------------------------------|------------------------|-----------------------|-----------------|--------------|
| Test Name |                                  | Test Name              |                       | Test Name       |              |
| TEST CODE | TES                              | Г NAME                 |                       | DISORDER        | SAMPLE TYPE* |
| 6603      | ABCA4 Comprehensive (Seq. & Del  | /Dup Analysis)         | ABCA4-Related Disord  | ders            | BE, DNA      |
| 2924      | BEST1 Comprehensive (Seq. & Del  | /Dup Analysis)         | BEST1-Related Disord  | lers            | BE, DNA      |
| 2419      | CEP290 Comprehensive (Seq. & De  | l/Dup Analysis) CEP290 | CEP290-Related Disor  | rders           | BE, DNA      |
| 6655      | CDH23 Sequence Analysis          |                        | CDH23-Related Disord  | ders            | BE, DNA      |
| 6660      | CLRN1 Sequence Analysis          |                        | CLRN1-Related Disord  | ders            | BE, DNA      |
| 7521      | COL2A1 Comprehensive (Seq. & De  | l/Dup Analysis)        | COL2A1-Related Diso   | rders           | BE, DNA      |
| 2389      | CDHR1 Comprehensive (Seq. & Del  | /Dup Analysis)         | Cone-Rod Dystrophy 1  | 15              | BE, DNA      |
| 2849      | CRB1 Comprehensive (Seq. & Del/I | Dup Analysis)          | CRB1-Related Disorde  | ers             | BE, DNA      |
| 5280      | OAT Sequence Analysis            |                        | Gyrate Atrophy of Cho | roid and Retina | BE, DNA      |
| 2789      | IMPDH1 Comprehensive (Seq. & De  | l/Dup Analysis)        | IMPDH1-Related Diso   | rders           | BE, DNA      |
| 2394      | LCA5 Comprehensive (Seq. & Del/I | )up Analysis)          | LCA5-Related Disorde  | rs              | BE, DNA      |





 $\odot$ 

/

Patient Last Name

Patient First Name

INHERITED EYE DISORDERS TESTING REQUISITION

Date of Birth (MM / DD / YYYY)

/

**Biological Sex** 

SINGLE GENE ANALYSIS CONTINUED

MI

| TEST CODE TEST NAME |   | DISORDER  | SAMPLE TYPE* |
|---------------------|---|---|--------------|
| 6039                | OCRL Sequence Analysis  | Lowe Syndrome   | BE, DNA      |
| 2839                | LRAT Comprehensive (Seq. & Del/Dup Analysis) LRAT-Related Disorders |   | BE, DNA      |
| 6083                | X-Linked, GPR143 Comprehensive (Seq. & Del/Dup Analysis)            | Oculocutaneous Albinism   | BE, DNA      |
| 3529                | Type 3, OPA3 Comprehensive (Seq. & Del/Dup Analysis)                | Optic Atrophy   | BE, DNA      |
| 2414                | ABHD12 Comprehensive (Seq. & Del/Dup Analysis)                      | Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa, and Cataract Disorder | BE, DNA      |
| 2959                | RDH12 Comprehensive (Seq. & Del/Dup Analysis)                       | RDH12-Related Disorders   | BE, DNA      |
| 2974                | EYS Comprehensive (Seq. & Del/Dup Analysis)                         | Retinitis Pigmentosa  | BE, DNA      |
| 2994                | FAM161A Comprehensive (Seq. & Del/Dup Analysis)                     | Retinitis Pigmentosa  | BE, DNA      |
| 2984                | MERTK Comprehensive (Seq. & Del/Dup Analysis)                       | Retinitis Pigmentosa  | BE, DNA      |
| 2459                | PDE6B Comprehensive (Seq. & Del/Dup Analysis)                       | Retinitis Pigmentosa  | BE, DNA      |
| 2399                | PROM1 Comprehensive (Seq. & Del/Dup Analysis)                       | Retinitis Pigmentosa  | BE, DNA      |
| 2939                | PRPH2 Comprehensive (Seq. & Del/Dup Analysis)                       | Retinitis Pigmentosa  | BE, DNA      |
| 2479                | RGR Comprehensive (Seq. & Del/Dup Analysis)                         | Retinitis Pigmentosa  | BE, DNA      |
| 2449                | RP2 Comprehensive (Seq. & Del/Dup Analysis)                         | Retinitis Pigmentosa  | BE, DNA      |
| 2359                | RPGR Comprehensive (Seq. & Del/Dup Analysis)                        | Retinitis Pigmentosa  | BE, DNA      |





# 

## INHERITED EYE DISORDERS TESTING REQUISITION

|                          |                    |    | / /                            |                |
|--------------------------|--------------------|----|--------------------------------|----------------|
| Patient Last Name        | Patient First Name | MI | Date of Birth (MM / DD / YYYY) | Biological Sex |
|                          |                    |    |                                |                |
| SINGLE GENE ANALYSIS CON | TINUED ·····       |    |                                |                |

| TEST CODE | TEST NAME                                     | DISORDER                        | SAMPLE TYPE* |
|-----------|---|---------------------------------|--------------|
| 2934      | RPE65 Comprehensive (Seq. & Del/Dup Analysis) | RPE65-Related Disorders         | BE, DNA      |
| 2899      | PRKCG Comprehensive (Seq. & Del/Dup Analysis) | Spinocerebellar Ataxia 14 (SCA) | BE, DNA      |
| 6650      | USH2A Sequence Analysis                       | USH2A-Related Disorders         | BE, DNA      |

\* Refer to Sample Specifications Table below

#### SAMPLE SPECIFICATIONS TABLE

| ABBREVIATION  | SAMPLE NAME                        | RECOMMENDED AMOUNT |                   |  | SPECIAL NOTES   |  |
|---------------|------------------------------------|--------------------|-------------------|--|---|--|
| ADDICEVIATION |                                    | (2 YRS - ADULT)    | (NEWBORN - 2 YRS) | 51117 110 11051 10051  | SFECIAL NOTES   |  |
| BE            | Blood in EDTA tube<br>(purple-top) | 3 - 5 cc           | 3 сс              | Ship at room temperature in an insulated container by<br>overnight courier. Do not heat or freeze.   | For clarification or follow-up of CMA results, sodium heparin (green<br>top) tubes are highly recommended. Send 3 - 5 cc (adults/children)<br>and 1 - 2 cc (infant<2 years).  |  |
| CF            | Cultured Skin Fibroblast           | 2 T25              | flasks            | Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.  | Send 2 T25 flasks at 80 - 100% confluence   |  |
| DNA           | DNA, Extracted                     | At least 20 ug     | of purified DNA   | Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.  | Minimal concentration of 50 ng / uL; A260 / A280 of ~1.7 - 2.0  |  |
| SA            | Saliva                             | See Special Notes  |                   | Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.  | Collected with Oragene • DX DNA Self-Collection Kit   |  |
| т             | Tissue                             | 50 mg              |                   | Ship frozen sample in insulated container with 3 - 5 lbs.<br>of dry ice by overnight courier.  | Tissue should be flash frozen in liquid nitrogen at collection with no media added, and stored at -80° C.   |  |
| SB            | Skin Biopsy                        | 5n                 | 1m³               | Ship at ambient temperature (18-25° C / 64-77° F).<br>Protect paraffin tissue from excessive heat. Ship in<br>cooled container during summer months. | Collect skin from a central location (e.g., buttock or upper thigh) rather<br>than from a distal location (e.g., foot) to enhance cell viability. Place<br>sample in a separate sterile container with RPMI media.<br>In the absence of RPMI media, place sample in a sterile container with<br>a small amount of sterile saline.<br>Unacceptable Conditions: Specimens placed in formalin or other<br>fixatives. |  |

CONNECT

# INFORMED CONSENT FOR INHERITED EYE DISORDERS TESTING

|  |  |   | 1 1   |   |  |  |  |  |
|--|--|---|---|---|--|--|--|--|
| Patient Last Name  | Patient First Name   | MI  | Date of Birth (MM / DD / YYYY)  | Biological Sex  |  |  |  |  |
| INFORMED CONSENT FOR GENETIC   | TESTING  |   |   |   |  |  |  |  |
| TEST INFORMATION   |  |   |   |   |  |  |  |  |
| This consent form will provide you counselor. In order to ensure that y process and potential results below  | with information regarding gene<br>ou have understood the purpose<br>v.  | tic testing, which you she<br>and significance of gene  | ould discuss with your healthcare pro<br>tic testing, we have provided informa  | ovider or a genetic<br>ation about the testing  |  |  |  |  |
| The purpose of genetic testing is to<br>abnormal change (variant) that cou<br>used to identify or rule out a specifi<br>genetic condition. Genetic screenin  | identify the cause of a suspecte<br>ld explain the disease you or me<br>ic genetic condition. Genetic scre<br>g tests are not typically diagnost   | d disease in you or your i<br>mbers of your family are<br>ening tests are used to a<br>ic, and results may requ | family. The testing analyzes your gen<br>experiencing. Genetic testing can be<br>assess the chance for a person to dev<br>ire additional testing. | etic material (DNA) for an<br>a diagnostic test, which is<br>relop or have a child with a |  |  |  |  |
| The purpose of this test is to see if y<br>determine the chance that you or yo<br>purposes of this consent.  | you or your child may have a gen<br>our child will develop or pass on  | etic variant or chromosc<br>a genetic disorder in the   | ome rearrangement. This may cause<br>future. "Your child" can also mean y   | a genetic disorder or may<br>our unborn child, for the                                    |  |  |  |  |
| In a genetic test, depending on the o  | case, you can be tested for:   |   |   |   |  |  |  |  |
| • A single gene/variant responsit  | ole for a specific, suspected gene   | etic disease.   |   |   |  |  |  |  |
| <ul> <li>Multiple genes in parallel.</li> </ul>  |  |   |   |   |  |  |  |  |
| The sample/specimen that is neede<br>tissue, saliva or buccal swab.  | ed to perform the genetic test is s  | stated in the test order fo   | orm and is typically blood or purified  | DNA, but may also be  |  |  |  |  |
| RESULTS  |  |   |   |   |  |  |  |  |
| There are several categories of tes  | t results that may be reported in  | cluding:  |   |   |  |  |  |  |
| <ul> <li>Positive: Positive or "abnormal"<br/>you/your child are at an increas</li> </ul>  | • <b>Positive:</b> Positive or "abnormal" results mean there is a change in the genetic material found that is related to your/your child's medical issues or that you/your child are at an increased risk of developing the disorder in the future. It is possible to test positive for more than one genetic variant   |   |   |   |  |  |  |  |
| • Negative: Negative or "normal" there is no genetic change, but i   | results mean no relevant geneti<br>it may mean that the type of test   | c change related to your<br>ng performed could not  | /your child's medical issues was dete<br>detect it.   | ected. This does not mean   |  |  |  |  |
| <ul> <li>Results of Unclear Significance<br/>variants of uncertain significance<br/>child's medical concerns.</li> </ul>   | • Results of Unclear Significance: Testing can detect change(s) in DNA which we do not yet fully understand. These alterations are also referred to as variants of uncertain significance (VUS). Additional studies may be recommended if a VUS is identified in a gene that may be associated with your/your child's medical concerns.  |   |   |   |  |  |  |  |
| • Secondary / Incidental Finding<br>medical or reproductive signific   | <b>s:</b> Testing can sometimes detect<br>cance, it is called a secondary or   | a change in a person's E<br>incidental finding.   | DNA unrelated to the reason for testir  | ıg. If this change has  |  |  |  |  |
| CONSIDERATIONS AND LIMITATION  | IS   |   |   |   |  |  |  |  |
| <ul> <li>Results may indicate affected s<br/>understand that genetic tests, e<br/>your family members.</li> </ul>  | tatus, increased risk to someday<br>even if negative, are not exhausti   | be affected with, and/or<br>ve. It is not possible to ex  | reproductive risk for a genetic disor<br>cclude risks for all possible genetic d  | der. It is important to iseases for yourself and  |  |  |  |  |
| <ul> <li>A positive test result is an indicate testing. You might consider add</li> </ul>  | ation that the individual(s) being<br>itional independent testing, cons  | tested may be predispos<br>ult a personal physician   | ed to or have the specific disease or<br>, or pursue genetic counseling.  | condition which prompted  |  |  |  |  |
| <ul> <li>It is possible that the knowledge results with your healthcare presented and the second second</li></ul> | e of the test results may result ir<br>ovider or genetic counselor.  | n psychological stress fo   | r you and your family. It is always rec   | commended to discuss the  |  |  |  |  |
| <ul> <li>If several family members are t<br/>cases, genetic testing can revea<br/>necessary to report this to the p</li> </ul>   | If several family members are tested, the correct interpretation of the results depends on the provided relationships between family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a discrepancy is identified, it may be necessary to report this to the physician who ordered the testing.   |   |   |   |  |  |  |  |
| <ul> <li>Genetic testing is highly accurate samples, inaccurate reporting of the samples.</li> </ul>   | te. Rarely, inaccurate results ma<br>of clinical/medical information, o  | y occur for various reaso<br>r rare technical errors.   | ons. These reasons include, but are n   | ot limited to, mislabeled   |  |  |  |  |
| <ul> <li>If you sign this consent form, bu<br/>complete, but you have not rece<br/>consent for testing after 5pm C</li> </ul>  | If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact your physician to cancel the test. If testing is complete, but you have not received your results yet, you can inform your physician that you no longer wish to receive the results. If you withdraw consent for testing after 5pm CST the next business day following sample receipt by the laboratory, you will be charged for the full cost of the test. |   |   |   |  |  |  |  |
| PATIENT CONFIDENTIALITY AND SI   | PECIMEN RETENTION ·····  |   |   |   |  |  |  |  |
| • Results will only be released to   | a licensed healthcare provider, t  | to those allowed access   | to test results by law, and to those au   | thorized in writing.  |  |  |  |  |
| <ul> <li>In rare cases, persons with gen<br/>enacted several laws that prohi<br/>prohibit unauthorized disclosur</li> </ul>  | etic diagnoses have experienced<br>bit discrimination based on gene<br>e of this information. For more in  | l problems with insurance<br>etic test results by health<br>nformation, you can visit                           | e coverage and employment. The U.<br>I insurance companies and employer<br>www.genome.gov/10002077.   | <ol> <li>Federal Government has</li> <li>In addition, these laws</li> </ol>               |  |  |  |  |

- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring heath care providers unless specific prior arrangements have been made.

CONNECT

#### INFORMED CONSENT FOR INHERITED EYE DISORDERS TESTING

|   |  |   | / /  |   |  |  |  |
|---|--|---|--|---|--|--|--|
| Patient Last Name   | Patient First Name   | MI  | Date of Birth (MM / DD / YYYY)   | Biological Sex                                  |  |  |  |
| INFORMED CONSENT FOR GE   | ENETIC TESTING   |   |  |   |  |  |  |
| PATIENT CONFIDENTIALITY   | AND SPECIMEN RETENTION (CONT.) ·····   |   |  |   |  |  |  |
| <ul> <li>Samples from residents<br/>retained for more than 6<br/>performed on the biolog</li> </ul>   | of New York State will not be included in<br>0 days after test completion, unless spec<br>ical sample.   | the de-identified rese<br>cifically authorized by | arch studies described in this authoriz<br>your selection. No tests other than tho | ation and will not be<br>se authorized shall be |  |  |  |
| <ul> <li>Information including re<br/>and healthcare database<br/>revealed in such data sh</li> </ul> | Information including results, indications for testing and clinical status obtained from this testing may be shared with healthcare providers, scientists and healthcare databases or used in scientific publications or presentations, but the personal identifying information of all persons studied will not be revealed in such data sharing or publications/presentations. |   |  |   |  |  |  |
| RESEARCH & RECONTACT CO   | NSENT  |   |  |   |  |  |  |
| For more information on re appropriate box.   | search at Baylor Genetics, please visit ba   | aylorgenetics.com. Ple                            | ease read the below statements carefu  | lly and check the                               |  |  |  |

Note: If left blank, consent is interpreted as "NO."

□ I agree to use of my de-identified specimen for research to improve genetic testing for all patients and contribute to scientific research.

I am a New York State Resident, and I give Baylor Genetics permission to store my specimen in accordance to the laboratory retention policy for internal quality assurance and possible research studies.

In addition to agreeing above, I agree to be contacted by Baylor Genetics regarding research opportunities.

#### PATIENT AUTHORIZATION

By signing this statement of consent, I acknowledge that I have read and understand the informed consent for genetic testing. I have received appropriate explanations from my physician regarding the purpose, scope, type and significance of the planned genetic testing and achievable results. All my questions have been answered and I have had the necessary time to make an informed decision about the genetic test.

I give permission to Baylor Genetics to conduct genetic testing as recommended by my physician.

Patient Signature

Date (DD/MM/YYYY)

Printed Name